礼来(LLY.US)Omvoh药物获加拿大卫生部批准用于治疗克罗恩病

智通财经
Jul 16, 2025

智通财经APP获悉,礼来公司(LLY.US)周二宣布,其药物Omvoh(mirikizumab,米瑞奇珠单抗)已获得加拿大卫生部批准,用于治疗克罗恩病患者。目前,Omvoh已被批准用于两种炎症性肠病的治疗,包括溃疡性结肠炎。

加拿大卫生部同时批准了Omvoh的新型无柠檬酸皮下注射制剂,该制剂与原版Omvoh含有相同的活性成分。

礼来公司表示,在VIVID-1临床试验中,针对中重度活动性克罗恩病患者,与安慰剂相比,Omvoh在多个终点指标上均展现出具有统计学意义和临床意义的疗效,达到了共同主要复合终点及所有主要次要终点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10